IXICO adds two prominent Alzheimer’s and vascular experts to its Scientific Advisory Board
Great companies attract great talent.
None more so than IXICO , a £10m marketcap, AI powered medical imaging analytics firm, which is materially outperforming the broader CRO sector.
Today the company announced that it had appointed two prominent global Alzheimer's Disease and vascular experts to its Scientific Advisory Board. Namely Professor Micheal Weiner (MD), who is a Professor Emeritus in Radiology and Biomedical Imaging, Medicine, Psychiatry and Neurology at the University of California, San Francisco. Alongside Professor Joanna Wardlaw (MD, CBE), who similarly is a Professor of Applied Neuroimaging at the University of Edinburgh and Consultant Neuroradiologist for NHS Lothian.
These appointments support IXICO's strategy to deepen its presence in Alzheimer's Disease and develop a series of biomarker algorithms to identify and measure vascular abnormalities. Which are a common contributing factor in neurodegenerative disease, where MRI can provide an established biomarker for vascular abnormalities.
Chief Scientific Officer Robin Wolz commenting: "Collaborating with distinguished experts in the field directly supports our work to develop and validate vascular biomarker algorithms that address a critical gap in current AD trials.”
Finally wrt the numbers, house broker Cavendish are forecasting FY26 EBITDA of -£1.6m on turnover of £6.9m (+9.5% vs £6.3m LY), augmented by a 24p/share price target. Net cash closed Sept’25 at £3.5m. FY25 results are due out on Tuesday 9th December.
Disclosure: IXICO is a Vox Markets client.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.
